

# Linear Mixed Model Analysis of Polygenic Hazard Score on Verbal Memory Decline in Alzheimer's Disease

Kesheng Wang  ▼ Chun Xu  ▼ Laurie A. Theeke  ▼ Danqing Xiao  ▼ Xingguang Luo  ▼ Changchun Xie  ▼ Alzheimer's Disease Neuroimaging Initiative

**Background:** Alzheimer's disease (AD) is a chronic, progressive, degenerative disease characterized by cognitive dysfunction, including verbal memory loss. Studies were lacking in examining the longitudinal effect of polygenic hazard score on the Rey Auditory Verbal Learning Test–Delayed Total (AVDELTOT) score (a common measure of verbal memory). A key step in analyzing longitudinal changes in cognitive measures using a linear mixed model (LMM) is choosing a suitable covariance structure.

**Objectives:** The study aims to determine the association between the polygenic hazard score and the AVDELTOT score accounting for repeated measures (the covariance structure).

**Methods:** The AVDELTOT scores were collected at baseline, 12 months, 24 months, 36 months, and 48 months from 283 participants with AD, 347 with cognitive normal, and 846 with mild cognitive impairment in the Alzheimer's Disease Neuroimaging Initiative. The Bayesian information criterion statistic was used to select the best covariance structure from 10 covariance structures in longitudinal analysis of AVDELTOT scores. The multivariable LMM was used to investigate the effect of polygenic hazard score status (low vs. medium vs. high) on changes in AVDELTOT scores while adjusted for age, gender, education, *APOE-ε4* genotype, and baseline Mini-Mental State Examination score.

**Results:** One-way analysis of variance revealed significant differences in AVDELTOT scores, Mini-Mental State Examination scores, and polygenic hazard scores among AD diagnoses at baseline. Bayesian information criterion favored the compound symmetry covariance structure in the LMM analysis. Using the multivariate LMM, the *APOE-ε4* allele and high polygenic hazard score value was significantly associated with AVDELTOT declines. Significant polygenic hazard score status by follow-up visit interactions was discovered.

**Conclusion:** Our findings provide the first evidence of the effect of polygenic hazard score status and *APOE-ε4* allele on declines in verbal memory in people with AD.

**Key Words:** Alzheimer's disease • *APOE-ε4* • covariance structure • linear mixed model • polygenic hazard score • verbal memory

*Nursing Research, January/February 2023, Vol 72, No 1, 66–73*

Alzheimer's disease (AD) is a chronic and progressive neurodegenerative disease with memory problems centered on episodic memory (Lane et al., 2018). It is known that physiological changes occur in the brain many

years before AD is diagnosed (Jack et al., 2013). However, the direct role of changes such as amyloid deposits and tau deposition has recently had conflicting reports as they were described as being present in cognitively unimpaired older adults (Sullivan et al., 2021). Knowing this makes it critical to understand the progression of the disease from a population health perspective. Understanding factors that can further elucidate AD progression characteristics will be needed for clinical care. Typically, diagnostic criteria of AD include assessment of general cognitive decline, observance of changes in personality, cognitive tests that elicit the loss of long- and short-term memories, loss of language memory and fluency, and onset of atypical behaviors (Jack et al., 2013; Weller & Budson, 2018). Once diagnosed, one way to consider progression is through measurement of verbal memory and verbal fluency, but longitudinal studies are needed on verbal memory and fluency tests (Mura et al., 2022).

AD has a substantial genetic component with heritability of 58%–79% (Gatz et al., 2006), whereas 95% of all people with

**Kesheng Wang, PhD**, is Associate Professor, Department of Family and Community Health, School of Nursing, Health Sciences Center, West Virginia University, Morgantown.

**Chun Xu, PhD**, is Associate Professor, Department of Health and Biomedical Sciences, College of Health Professions, University of Texas Rio Grande Valley, Brownsville.

**Laurie A. Theeke, PhD, RN**, is Professor and Associate Dean, The George Washington University School of Nursing, VSTC, Ashburn, Virginia.

**Danqing Xiao, PhD, RT**, is Associate Professor, Department of STEM, School of Arts and Sciences, Regis College, Weston, Massachusetts, and Neuroimaging Center, McLean Hospital, Belmont, Massachusetts.

**Xingguang Luo, PhD, MD**, is Scientist, Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut.

**Changchun Xie, PhD**, is Professor, Division of Biostatistics and Bioinformatics, Department of Environmental Health, University of Cincinnati, Ohio.

**Alzheimer's Disease Neuroimaging Initiative.**

Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.

DOI: 10.1097/NNR.0000000000000623

AD are defined as late-onset AD (defined as AD with an onset age of  $\geq 65$  years; Bettens et al., 2010). Genome-wide association studies have identified more than 30 known risk loci for AD (Jansen et al., 2019; Kunkle et al., 2019), and recently, genome-wide data in a genetic epidemiology framework were used to develop a polygenic hazard score (PHS) to quantify the age-associated risk for developing AD (Desikan et al., 2017). The PHS has been used to predict overall risk of AD, age at onset, clinical phenotypes, and the design of AD clinical trials (Desikan et al., 2017; Kauppi et al., 2018; Tan et al., 2017).

It is clinically significant to understand the links between verbal memory and learning with the progression of AD because impaired verbal memory is linked to progressive aphasia (Foxe et al., 2021). AD studies frequently use the Rey Auditory Verbal Learning Test (RAVLT) to assess immediate or delayed recall and recognition memory (van den Berg et al., 2020). Though AD's risks, progression, and phenotypes have been a research focus, no study has focused on the PHS on RAVLT measures. The RAVLT is commonly used to assess verbal memory and has been extensively validated for use in cognitively normal (CN) and impaired people (Poreh et al., 2012). It is known that age, education, and gender may influence RAVLT performance (Magalhães & Hamdan, 2010), which has been used to distinguish AD, mild cognitive impairment (MCI), and CN (Ding et al., 2019; Messinis et al., 2016).

In addition to the lack of understanding of PHS on Rey Auditory Verbal Learning Test-Delayed Total (AVDELTOT) scores, studies have not reported analysis of longitudinal changes of continuous outcomes of AD with a suitable covariance structure using a linear mixed model (LMM; George & Aban, 2015; Littell et al., 2000). LMMs, including both fixed and random effects, have been proposed to analyze the longitudinal effect of *APOE-ε4* allele on AD-related phenotypes (e.g., Fokoh et al., 2021; Mormino et al., 2014; Paranjpe et al., 2019; Sutphen et al., 2015). For example, one study reported significant interactions between amyloid- $\beta$  ( $A\beta$ ) and *APOE-ε4* status in predicting change in logical memory scores in healthy individuals using LMM (Mormino et al., 2014). Subsequently, a pilot study on patients with heart failure suggested no significant association of *APOE-ε4* allele with delayed (recall) memory (Pressler et al., 2017). Through repeated measures of longitudinal study over time are correlated, LMMs can be used to account for repeated measures in longitudinal studies (Wang, 2016; West et al., 2014). This study fills the current gap in the scientific knowledge related to the association between repeated measures for AD by comparing 10 covariance structures in longitudinal analysis of the AVDELTOT score in AD using LMM and examining the effect of PHS status on longitudinal declines in AVDELTOT scores.

## METHODS

### Sample

Data used in this study were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). The ADNI was launched in 2003 as a public-private partnership

and began in 2004. Currently, the ADNI has undergone four phases: ADNI1, ADNI GO, ADNI2, and ADNI3. The ADNI project is ongoing and employs a multicenter, longitudinal design aiming to understand relationships among clinical and cognitive assessments, imaging, genetic information, and biochemical biomarkers currently used for the early diagnosis of AD. The primary goal of ADNI has been to test whether the collected information can be combined to measure and understand the progression of MCI and early AD. The ADNI study provides services in the United States and Canada. There was an institutional review board exemption for the current study because of secondary data analysis.

## Measures

**Social Demographics** This analysis included three demographic measures: gender, age, and education. Gender was self-reported as either male or female. Age was classified into three groups:  $\leq 65$  years, 66–75 years, and 76+ years. Years of education were classified into  $\leq 12$  years, 13–16 years, and 17+ years. Only non-Hispanic White individuals were used for the present analysis.

**Cognitive Phenotypes** The Folstein Mini-Mental State Examination (MMSE) is a brief questionnaire that measures global cognitive impairment by evaluating five cognitive domains: orientation, registration, attention and calculation, recall, and language (Folstein et al., 1983). The MMSE has well-established psychometrics, with scores on the Folstein MMSE ranging from 0–30, with 30 being no cognitive impairment.

The RAVLT—a commonly used test of verbal episodic memory—includes a list of 15 unrelated words presented orally to the subject (Schmidt, 1996). The test has five consecutive learning trials: repetitions to learn the unstructured verbal material, followed by a 30-minute delayed period for free recall, and a subsequent recognition trial that includes 30 words (15 from the learning trials) and 15 unrelated words. A learning score is calculated using the difference between the last and the first immediate recall trials. In this study, we used the 30-minute auditory verbal delayed recall total (AVDELTOT) score, which ranges from 0 to 15.

**APOE Genotypes** The data of APOE genotypes were extracted from the ADNI database. *APOE-ε4* carriers were defined as individuals with at least one  $\epsilon 4$  allele ( $\epsilon 4/\epsilon 4$ ,  $\epsilon 4/\epsilon 3$ , or  $\epsilon 4/\epsilon 2$  as *APOE-ε4-1+*), whereas noncarriers were defined as individuals with no  $\epsilon 4$  allele (*APOE-ε4-0*; Table 1).

**Polygenic Hazard Score** The PHS data were downloaded from the ADNI website (desikanlab.html; Desikan et al., 2017). The PHS data were based on AD-associated single-nucleotide polymorphisms from previous genome-wide association study data, such as the International Genomics of Alzheimer's Project and the Alzheimer's Disease Genetics Consortium. Everyone

TABLE 1. Descriptive Statistics at Baseline

| Variable          | CN           | MCI          | AD           |
|-------------------|--------------|--------------|--------------|
| Gender            |              |              |              |
| Male              | 185          | 493          | 160          |
| Female            | 162          | 353          | 123          |
| APOE-ε4 allele    |              |              |              |
| 0                 | 255          | 429          | 94           |
| 1+                | 92           | 417          | 189          |
| PHS level         |              |              |              |
| Low               | 115          | 148          | 31           |
| Medium            | 209          | 525          | 153          |
| High              | 23           | 173          | 99           |
| PHS               |              |              |              |
| Mean ± SD         | 0.03 ± 0.67  | 0.43 ± 0.78  | 0.80 ± 0.85  |
| Age (years)       |              |              |              |
| <65               | 6            | 127          | 36           |
| 65–75             | 176          | 360          | 96           |
| 75+               | 166          | 359          | 151          |
| Education (years) |              |              |              |
| ≤12               | 37           | 134          | 70           |
| 13–16             | 152          | 339          | 127          |
| 17+               | 158          | 373          | 86           |
| MMSE              |              |              |              |
| Mean ± SD         | 29.10 ± 1.10 | 27.80 ± 1.79 | 23.21 ± 2.03 |
| AVDELTOT          |              |              |              |
| Mean ± SD         | 12.87 ± 2.38 | 10.75 ± 3.52 | 7.12 ± 3.80  |

Note. CN = cognitive normal; MCI = mild cognitive impairment; AD = Alzheimer’s disease; PHS = polygenic hazard score; SD = standard deviation; MMSE = Mini Mental State Examination; AVDELTOT = Rey Auditory Verbal Learning Test–Delayed Total.

has a PHS to reflect an individual’s risk for developing AD based on age and genotype. The PHS has been replicated in Phase 2 of the Alzheimer’s Disease Genetics Consortium, the National Institute on Aging Alzheimer’s Disease Centers, and the ADNI. In this study, the PHS was categorized as low, medium, and high, according to the tertile distribution of PHS in all participants.

Statistical Methods

**Baseline Descriptive Statistics** The categorical variables were presented in their raw values, along with the proportions for categorical variables, and continuous variables were introduced in the form of mean ± standard deviation. A chi-square test was used to examine the associations of categorical variables with AD diagnostics. At the same time, a one-way analysis of variance was performed to determine the differences in continuous variables among AD diagnostics.

**Linear Mixed Model** The LMM, including fixed and random effects for a continuous outcome variable in a longitudinal study, can be expressed as Equation 1.

$$Y_{ijk} = \mu + \alpha_i + b_{ij} + \gamma_k + (\alpha\gamma)_{ik} + \varepsilon_{ijk} \tag{1}$$

where

$Y_{ijk}$  is the value of the outcome for individual  $j$  at follow-up time  $k$  with treatment (or covariate)  $i$ ,  
 $\mu$  is the intercept of the model,  
 $\alpha_i$  is the effect for treatment (or covariate)  $i$ ,  
 $b_{ij}$  is a random effect for subject  $j$  with treatment (or covariate)  $i$ ,  
 $\gamma_k$  is the effect of time (follow-up visit)  $k$ ,  
 $(\alpha\gamma)_{ik}$  is the effect for treatment (or covariate)  $\times$  time interaction,

$\varepsilon_{ijk}$  is the random error associated with outcome at time  $k$  on the  $j$ th individual for treatment (or covariate)  $i$ .

The Bayesian information criterion (BIC) statistic (Simonoff, 2003) was used to select the best covariance structure from 10 commonly used covariance structures: ante-dependence (ANTE), autoregressive (AR), heterogeneous autoregressive (ARH), first-order, autoregressive moving average (ARMA), compound symmetry (CS), heterogeneous compound symmetry (CSH), Huynh-Feldt (HF), banded Toeplitz structure (TOEP), unstructured (UN), and variance components (VC). The model with smaller BIC fits the data better.

The multivariable repeated-measures LMMs, including PHS status as fixed effect and subject as random effect, were used to examine the longitudinal changes in AVDELTOT score as a continuous trait adjusting for age, gender, education, *APOE-ε4*, and MMSE. The interaction between PHS status and follow-up visits was tested. The repeated-measures longitudinal analyses were performed using PROC MIXED in SAS (Version 9.4). All statistical analysis was performed using SAS 9.4.

RESULTS

Baseline Descriptive Statistics

After merging data, the total sample size of the baseline data was 1,476, including 283 with AD, 347 with CN, and 846 with MCI (Table 1). All persons were non-Hispanic White with AVDELTOT scores, *APOE-ε4*, and PHS values. The AD group had lower mean values in the MMSE indicative of cognitive impairment, whereas the CN and MCI groups had MMSE scores that could be interpreted as cognitively unimpaired. The AD group showed lower mean scores for the AVDELTOT but higher PHSs than those in the CN and MCI groups.

Covariance Structure Selection in LMM

In the LMMs, the BIC statistics favored the CS structure (Table 2). The BIC value for CS was 25,076.3, which was lower than any other covariance structure. By the CS structure, the correlation between two repeated measures was constant irrespective of the lag or length of time between them. We chose CS as the favorite model for further analysis.

LMM Analysis of AVDELTOT Scores

Using a CS model, the multivariable LMM analysis results are presented in Table 3. All the variables were associated with

TABLE 2. Covariance Structure Selection in Linear Mixed Model Analysis

| Structure | -2 Log likelihood | BIC     |
|-----------|-------------------|---------|
| ANTE(1)   | 25437.0           | 25502.6 |
| AR(1)     | 25472.3           | 25486.9 |
| ARH(1)    | 25469.2           | 25513.0 |
| ARMA(1,1) | 25059.8           | 25081.7 |
| CS        | 25061.7           | 25076.3 |
| CSH       | 25058.7           | 25102.5 |
| HF        | 25046.5           | 25090.3 |
| TOEP      | 25048.7           | 25085.2 |
| UN        | 24994.6           | 25104.1 |
| VC        | 26729.1           | 26736.4 |

Note. BIC = Bayesian information criterion statistic; ANTE = ante-dependence; AR = autoregressive; ARH = heterogeneous autoregressive; ARMA = first-order Autoregressive moving average; CS = compound symmetry; CSH = heterogeneous compound symmetry; HF = Huynh-Feldt; TOEP = a banded Toeplitz structure; UN = unstructured; VC = variance components.

AVDELTOT scores ( $p < .05$ ). The *APOE-ε4* was significantly associated with AVDELTOT declines ( $t = -3.80, p = .0001$ ), whereas low and medium PHS status compared with high PHS were positively associated with AVDELTOT scores ( $t = 2.26, p = .0240$  and  $t = 3.14, p = .0017$ , respectively). Furthermore, AD and MCI were negatively associated with AVDELTOT scores compared with CN ( $t = -13.55, p < .0001$  and  $t = -8.90, p < .0001$ , respectively).

The AVDELTOT scores significantly declined at 12, 36, and 48 months compared with baseline ( $p = .0065, p < .0001$ , and  $p = .0033$ , respectively). Significant interactions were found between PHS-Low and 12 months ( $p = .0200$ ), PHS-Low and PHS-Medium and 36 months ( $p = .0048$  and  $p = .0104$ , respectively), and PHS-Low and PHS-Medium and 48 months ( $p = .0217$  and  $p = .0436$ , respectively). A graphical display of two-way interactions between PHS status and visits is further shown in Figure 1.

DISCUSSION

To the best of our knowledge, this is the first longitudinal analysis of the AVDELTOT scores in AD using repeated measures LMM to examine the association between PHS status and AVDELTOT across time (longitudinal). In addition, we have considered the dependency of measures from the same subject (repeated measures/covariance structure). Researchers have elucidated that PHSs help assess risk for AD and clinical phenotypes and are predictive of general longitudinal decline (Desikan et al., 2017; Kauppi et al., 2018; Tan et al., 2017), but this study adds valuable information about specific declines in verbal memory. We found significant differences in AVDELTOT scores among AD, MCI, and CN at baseline, which is interesting because it may be challenging to differentiate early AD from MCI clinically. Furthermore, the CS covariance structures outperformed the other models' LMM analysis of AVDELTOT scores. In addition, individuals with at least one *APOE-ε4* allele had significant AVDELTOT score declines

compared with those without *APOE-ε4* allele, which is congruent with the known critical importance of the  $\epsilon 4$  allele of APOE gene and AD progression (Sienski et al., 2021). Because we know that AD has a genetic component, the finding that higher PHSs are not only associated with AD risk but also associated with a decline in AVDELTOT scores is important. Discovering that those with medium PHSs did not have as much decline in AVDELTOT scores affirms the complex and multifactorial risks for AD.


The LMM is commonly used to deal with correlated data in repeated measures of longitudinal studies (Wang, 2016; West et al., 2014). However, one crucial step in analysis of longitudinal changes in continuous outcomes using LMM is to choose a suitable covariance structure (George & Aban, 2015; Littell et al., 2000). A helpful tool for selecting a covariance structure

TABLE 3. Linear Mixed Model Analysis of Polygenic Hazard Score With Rey Auditory Verbal Learning Test–Delayed Total Score

| Variable                                      | $\beta \pm SE$   | $t$    | $p$    |
|-----------------------------------------------|------------------|--------|--------|
| Gender (ref = male)                           |                  |        |        |
| Female                                        | $-0.37 \pm 0.15$ | -2.48  | .0133  |
| <i>APOE-ε4</i> (ref = 0)                      |                  |        |        |
| 1+                                            | $-0.72 \pm 0.19$ | -3.80  | .0001  |
| PHS level (ref = High)                        |                  |        |        |
| Low                                           | $0.75 \pm 0.33$  | 2.26   | .0240  |
| Medium                                        | $0.77 \pm 0.25$  | 3.14   | .0017  |
| Age (ref = <65)                               |                  |        |        |
| 65–75                                         | $-0.07 \pm 0.07$ | -0.30  | .7616  |
| 75+                                           | $0.68 \pm 0.07$  | -2.77  | .0057  |
| Education (ref = ≤12)                         |                  |        |        |
| 13–16                                         | $0.33 \pm 0.22$  | 1.56   | .1181  |
| 17+                                           | $0.53 \pm 0.22$  | 2.41   | .0160  |
| Diagnosis (ref = CN)                          |                  |        |        |
| AD                                            | $-3.62 \pm 0.27$ | -13.55 | <.0001 |
| MCI                                           | $-1.64 \pm 0.18$ | -8.90  | <.0001 |
| MMSE                                          | $0.30 \pm 0.02$  | 19.55  | <.0001 |
| Visit (ref = baseline)                        |                  |        |        |
| 12 months                                     | $-0.52 \pm 0.19$ | -2.72  | .0065  |
| 24 months                                     | $-0.34 \pm 0.21$ | -1.64  | .1020  |
| 36 months                                     | $-1.04 \pm 0.25$ | -4.09  | <.0001 |
| 48 months                                     | $-0.83 \pm 0.30$ | -2.94  | .0033  |
| Visit × PHS Level (ref = Baseline × PHS-High) |                  |        |        |
| 12 months × PHS-Low                           | $0.62 \pm 0.27$  | 2.33   | .0200  |
| 12 months × PHS-Medium                        | $0.40 \pm 0.22$  | 1.82   | .0691  |
| 24 months × PHS-Low                           | $0.48 \pm 0.28$  | 1.69   | .0905  |
| 24 months × PHS-Medium                        | $0.15 \pm 0.24$  | 0.64   | .5247  |
| 36 months × PHS-Low                           | $0.95 \pm 0.34$  | 2.82   | .0048  |
| 36 months × PHS-Medium                        | $0.73 \pm 0.28$  | 2.56   | .0104  |
| 48 months × PHS-Low                           | $0.87 \pm 0.38$  | 2.32   | .0217  |
| 48 months × PHS-Medium                        | $0.66 \pm 0.33$  | 2.02   | .0436  |

Note.  $p$  Value is based on  $t$  test in multivariate linear mixed model adjusted for gender, age, education, diagnosis, visit, and MMSE.  $\beta$  = adjusted regression coefficient;  $SE$  = standard error; ref = reference; PHS = polygenic hazard score; CN = cognitive normal; AD = Alzheimer's disease; MCI = mild cognitive impairment; MMSE = Mini Mental State Examination.





**FIGURE 1.** PHS status by follow-up visit interaction for AVDELTOT score. The x-axis is PHS status. The y-axis is the estimated marginal means of the AVDELTOT score. PHS = polygenic hazard score; AVDELTOT = Rey Auditory Verbal Learning Test-Delayed Total; bl = baseline; m12, m24, m36 and m48 = 12, 24, 36, and 48 months, respectively.

is the use of information criteria such as the Akaike information criterion (AIC), the small sample corrected AIC (AICC), and the BIC (George & Aban, 2015; Gomez et al., 2005; Littell et al., 2000). It has been suggested that the consistent information criteria (BIC) seemed to be more accurate than efficient criteria (AIC and AICC; George & Aban, 2015; McNeish & Harring, 2020). For example, AIC, AICC, and BIC have been used to compare CS, AR, TOEP, and UN covariance structures in analysis of longitudinal imaging data (George & Aban, 2015). In this study, we compared 10 covariance structures in longitudinal analysis of the AVDELTOT score in AD using LMM. We found that CS had the lowest BIC value and was the best covariance structure. The CS structure assumed a correlation between two separate measurements, but the correlation was constant regardless of how far apart the measurements were. Then, we examined the effect of PHS status on longitudinal declines in AVDELTOT scores using the CS covariance structure.

LMMs have been used to analyze longitudinal correlated data on the effect of *APOE-ε4* allele on AD-related phenotypes (e.g., Fokoh et al., 2021; Mormino et al., 2014; Paranjpe et al., 2019; Sutphen et al., 2015). One study reported significant interactions between  $A\beta$  and *APOE-ε4* allele status in predicting change in logical memory scores in healthy individuals using LMM (Mormino et al., 2014). A pilot study on heart failure patients also suggested no significant association of *APOE-ε4* allele with delayed (recall) memory (Pressler et al., 2017). Moreover, the *APOE-ε4* allele was associated with decreased inter-hemispheric resting-state functional connectivity, which was attributed to carrier memory performance (Luo et al., 2016). One recent study found the effect of *APOE* genotypes on

the logical memory declines related to AD (Fokoh et al., 2021). This study added that *APOE-ε4* allele was associated with longitudinal declines in verbal memory in AD. This finding is consistent with other recent studies that reported more rapid AD progression for those that pose the *APOE-ε4* (Chen et al., 2021).

The PHS has been used to predict individual risk of developing AD, AD age at onset, and clinical phenotypes, as well as help design AD clinical trials (Desikan et al., 2017; Kauppi et al., 2018; Tan et al., 2017). This study further added that PHSs are associated with the decline in AVDELTOT scores, and there are two-way interactions between PHS status and follow-up visits.

The findings from this study are somewhat congruent with other research. In this study, we report significantly lower AVDELTOT scores of verbal memory in AD and MCI compared with CN individuals. The RAVLT score has been used to distinguish AD from MCI and dementia (Ding et al., 2019; Messinis et al., 2016). Likewise, the 30-minute delayed recall score of the RAVLT has been used to predict  $A\beta$  status (Kandel et al., 2015). Moreover, one study examined gender differences in florbetapir positron emission tomography amyloid positivity ( $A^+$ ) on verbal learning and memory performance and hippocampal volume in CN and early MCI individuals (Caldwell et al., 2017). Another study investigated the relationship between the asymmetry magnitude in hippocampal subfields and verbal memory decline as assessed by RAVLT (Sarica et al., 2018).

There are several strengths in this study. First, the ADNI is a longitudinal study that provides a large sample for analysis. Second, we conducted covariance structure selection in LMM analysis of AVDELTOT scores. Third, this is the first study to examine the association of PHS status with the longitudinal

changes in AVDELTOT scores. Finally, we detected interactions between PHS status and follow-up visits.

Several limitations need to be acknowledged. First, the current study was time limited by the data set, which provided 4 years of follow-up. Second, this study found longitudinal declines only in the 75 years of age and above group. Furthermore, this study does not account for current treatment of AD patients. In addition, the results of this study cannot be generalized to all the patient population because it was restricted to non-Hispanic White people.

There are many future implications from this work. Future study designs could include plans to investigate how *APOE-ε4* allele and PHS affects early-onset AD patients and late-onset AD patients differently concerning the verbal memory test. Also, future studies could consider the incorporation of the PHS to better understand other specific aspects of disease progression.

## Conclusion

This study provides new information about verbal learning and progression of AD and MCI. This study compared 10 covariance structures in the LMM analysis of longitudinal changes in AVDELTOT scores, found CS covariance structure is the best, and identified differences in AVDELTOT scores among three diagnostic groups at baseline. Furthermore, we described the significant decline in AVDELTOT scores at 4-year follow-ups. Using LMM analysis, our findings provide the first evidence of the longitudinal effect of *APOE-ε4* allele and PHSs on the AVDELTOT scores related to AD and make it clear that verbal memory examination scores could be a good predictor for AD.

Accepted for publication July 2, 2022.

Data from this article's preparation were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in the analysis or writing of this report. A complete listing of ADNI investigators can be found at [http://adni.loni.usc.edu/wp-content/uploads/how\\_to\\_apply/ADNI\\_Acknowledgement\\_List.pdf](http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf)

This study is secondary data analysis. The original study and ADNI were funded by the ADNI, the National Institutes of Health (Grant U01 AG024904), and the Department of Defense ADNI (Award No. W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai, Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd. and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC; Johnson & Johnson Pharmaceutical Research & Development LLC; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer, Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California.

This multicentered research project was approved by institutional review boards at each site, and authorized written informed consent from participants was obtained (<http://adni.loni.usc.edu/>). There was an institutional review board exemption for current secondary data analysis. The authors have no conflict of interest to report.

Corresponding author: Kesheng Wang, PhD, Department of Family and Community Health, School of Nursing, Health Sciences Center, West Virginia University, P.O. Box 9600, Morgantown, WV 26506 (e-mail: kesheng.wang@hsc.wvu.edu).

## ORCID iDs

Kesheng Wang  <https://orcid.org/0000-0001-7118-3877>

Chun Xu  <https://orcid.org/0000-0001-7893-6341>

Laurie A. Theeke  <https://orcid.org/0000-0002-6965-0728>

Danqing Xiao  <https://orcid.org/0000-0002-6963-2933>

Xingguang Luo  <https://orcid.org/0000-0003-3585-042X>

Changchun Xie  <https://orcid.org/0000-0002-1843-4099>

## REFERENCES

- Bettens, K., Slegers, K., & Van Broeckhoven, C. (2010). Current status on Alzheimer disease molecular genetics: From past, to present, to future. *Human Molecular Genetics*, 19, R4-R11. 10.1093/hmg/ddq142
- Caldwell, J. Z. K., Berg, J.-L., Cummings, J. L., & Banks, S. J., Alzheimer's Disease Neuroimaging Initiative. (2017). Moderating effects of sex on the impact of diagnosis and amyloid positivity on verbal memory and hippocampal volume. *Alzheimer's Research & Therapy*, 9, 72. 10.1186/s13195-017-0300-8
- Chen, X. R., Shao, Y., & Sadowski, M. J. Alzheimer's Disease Neuroimaging Initiative. (2021). Segmented linear mixed model analysis reveals association of the *APOEε4* allele with faster rate of Alzheimer's disease dementia progression. *Journal of Alzheimer's Disease*, 82, 921-937. 10.3233/JAD-210434
- Desikan, R. S., Fan, C. C., Wang, Y., Schork, A. J., Cabral, H. J., Cupples, L. A., Thompson, W. K., Besser, L., Kukull, W. A., Holland, D., Chen, C.-H., Brewer, J. B., Karow, D. S., Kauppi, K., Witoelar, A., Karch, C. M., Bonham, L. W., Yokoyama, J. S., Rosen, H. J., & Dale, A. M. (2017). Genetic assessment of age-associated Alzheimer disease risk: Development and validation of a polygenic hazard score. *PLoS Medicine*, 14, e1002258. 10.1371/journal.pmed.1002258
- Ding, X., Chamigo, R. J., Schmitt, F. A., Kryscio, R. J., & Abner, E. L., Alzheimer's Disease Neuroimaging Initiative. (2019). Evaluating trajectories of episodic memory in normal cognition and mild cognitive impairment: Results from ADNI. *PLOS ONE*, 14, e0212435. 10.1371/journal.pone.0212435
- Fokoh, E., Xiao, D., Fang, W., Liu, Y., Lu, Y., & Wang, K., Alzheimer's Disease Neuroimaging Initiative. (2021). Longitudinal analysis of *APOE-ε4* genotype with the logical memory delayed recall score in Alzheimer's disease. *Journal of Genetics*, 100, 60. 10.1007/s12041-021-01309-y
- Folstein, M. F., Robins, L. N., & Helzer, J. E. (1983). The Mini-Mental State Examination. *Archives of General Psychiatry*, 40, 812. 10.1001/archpsyc.1983.01790060110016
- Foxe, D., Cheung, S. C., Cordato, N. J., Burrell, J. R., Ahmed, R. M., Taylor-Rubin, C., Irish, M., & Piguet, O. (2021). Verbal short-term memory disturbance in the primary progressive aphasia: Challenges and distinctions in a clinical setting. *Brain Sciences*, 11, 1060. 10.3390/brainsci11081060
- Gatz, M., Reynolds, C. A., Fratiglioni, L., Johansson, B., Mortimer, J. A., Berg, S., Fiske, A., & Pedersen, N. L. (2006). Role of genes and environments for explaining Alzheimer disease. *Archives of General Psychiatry*, 63, 168-174. 10.1001/archpsyc.63.2.168

- George, B., & Aban, I. (2015). Selecting a separable parametric spatio-temporal covariance structure for longitudinal imaging data. *Statistics in Medicine*, 34, 145–161. 10.1002/sim.6324
- Gomez, E. V., Schaalje, G. B., & Fellingham, G. W. (2005). Performance of the Kenward–Roger method when the covariance structure is selected using AIC and BIC. *Communications in Statistics—Simulation and Computation*, 34, 377–392. 10.1081/SAC-200055719
- Jack, C. R. Jr., Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., Shaw, L. M., Vemuri, P., Wiste, H. J., Weigand, S. D., Lesnick, T. G., Pankratz, V. S., Donohue, M. C., & Trojanowski, J. Q. (2013). Tracking pathophysiological processes in Alzheimer's disease: An updated hypothetical model of dynamic biomarkers. *Lancet Neurology*, 12, 207–216. 10.1016/S1474-4422(12)70291-0
- Jansen, I. E., Savage, J. E., Watanabe, K., Bryois, J., Williams, D. M., Steinberg, S., Sealock, J., Karlsson, I. K., Hägg, S., Athanasiu, L., Voyle, N., Proitsi, P., Witte, A., Stringer, S., Aarsland, D., Almdahl, I. S., Andersen, F., Bergh, S., Bettella, F., & Posthuma, D. (2019). Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer's disease risk. *Nature Genetics*, 51, 404–413. 10.1038/s41588-018-0311-9
- Kandel, B. M., Avants, B. B., Gee, J. C., Arnold, S. E., & Wolk, D. A., Alzheimer's Disease Neuroimaging Initiative. (2015). Neuropsychological testing predicts cerebrospinal fluid amyloid- $\beta$  in mild cognitive impairment. *Journal of Alzheimer's Disease*, 46, 901–912. 10.3233/JAD-142943
- Kauppi, K., Fan, C. C., McEvoy, L. K., Holland, D., Tan, C. H., Chen, C.-H., Andreassen, O. A., Desikan, R. S., & Dale, A. M., Alzheimer's Disease Neuroimaging Initiative. (2018). Combining polygenic hazard score with volumetric MRI and cognitive measures improves prediction of progression from mild cognitive impairment to Alzheimer's disease. *Frontiers in Neuroscience*, 12, 260. 10.3389/fnins.2018.00260
- Kunkle, B. W., Grenier-Boley, B., Sims, R., Bis, J. C., Damotte, V., Naj, A. C., Boland, A., Vronskaya, M., van der Lee, S. J., Anlie-Wolf, A., Bellenguez, C., Frizzati, A., Chouraki, V., Martin, E. R., Sleegers, K., Badarinarayan, N., Jakobsdottir, J., Hamilton-Nelson, K. L., & Moreno-Grau, S., Genetic and Environmental Risk in AD/Defining Genetic, Polygenic and Environmental Risk for Alzheimer's Disease Consortium. (2019). Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates A $\beta$ , tau, immunity and lipid processing. *Nature Genetics*, 51, 414–430. 10.1038/s41588-019-0358-2
- Lane, C. A., Hardy, J., & Schott, J. M. (2018). Alzheimer's disease. *European Journal of Neurology*, 25, 59–70. 10.1111/ene.13439
- Littell, R. C., Pendergast, J., & Natarajan, R. (2000). Modelling covariance structure in the analysis of repeated measures data. *Statistics in Medicine*, 19, 1793–1819. 10.1002/1097-0258(20000715)19:13<1793::aid-sim482>3.0.co;2-q
- Luo, X., Qiu, T., Xu, X., Huang, P., Gu, Q., Shen, Z., Yu, X., Jia, Y., Guan, X., Song, R., & Zhang, M., Alzheimer's Disease Neuroimaging Initiative. (2016). Decreased inter-hemispheric functional connectivity in cognitively intact elderly APOE  $\epsilon$ 4 carriers: A preliminary study. *Journal of Alzheimer's Disease*, 50, 1137–1148. 10.3233/JAD-150989
- Magalhães, S. S., & Hamdan, A. C. (2010). The Rey Auditory Verbal Learning Test: Normative data for the Brazilian population and analysis of the influence of demographic variables. *Psychology & Neuroscience*, 3, 85–91. 10.3922/j.psns.2010.1.011
- McNeish, D., & Harring, J. (2020). Covariance pattern mixture models: Eliminating random effects to improve convergence and performance. *Behavior Research Methods*, 52, 947–979. 10.3758/s13428-019-01292-4
- Messinis, L., Nasios, G., Mougias, A., Politis, A., Zampakis, P., Tsiamaki, E., Malefaki, S., Gourzis, P., & Papathanasopoulos, P. (2016). Age and education adjusted normative data and discriminative validity for Rey's Auditory Verbal Learning Test in the elderly Greek population. *Journal of Clinical and Experimental Neuropsychology*, 38, 23–39. 10.1080/13803395.2015.1085496
- Mormino, E. C., Betensky, R. A., Hedden, T., Schultz, A. P., Ward, A., Huijbers, W., Rentz, D. M., Johnson, K. A., & Sperling, R. A., Alzheimer's Disease Neuroimaging Initiative, Australian Imaging Biomarkers and Lifestyle Flagship Study of Ageing, & Harvard Aging Brain Study. (2014). Amyloid and APOE  $\epsilon$ 4 interact to influence short-term decline in preclinical Alzheimer disease. *Neurology*, 82, 1760–1767. 10.1212/WNL.0000000000000431
- Mura, T., Coley, N., Amieva, H., Berr, C., Gabelle, A., Ousset, P.-J., Vellas, B., & Andrieu, S., GuidAge/DSA Study Group. (2022). Cognitive decline as an outcome and marker of progression toward dementia, in early preventive trials. *Alzheimer's & Dementia*, 18, 676–687. 10.1002/alz.12431
- Paranjpe, M. D., Chen, X., Liu, M., Paranjpe, I., Leal, J. P., Wang, R., Pomper, M. G., Wong, D. F., Benzinger, T. L. S., & Zhou, Y., Alzheimer's Disease Neuroimaging Initiative. (2019). The effect of ApoE  $\epsilon$ 4 on longitudinal brain region-specific glucose metabolism in patients with mild cognitive impairment: A FDG-PET study. *Neuroimage. Clinical*, 22, 101795. 10.1016/j.nicl.2019.101795
- Poreh, A., Sultan, A., & Levin, J. (2012). The Rey Auditory Verbal Learning Test: Normative data for the Arabic-speaking population and analysis of the differential influence of demographic variables. *Psychology & Neuroscience*, 5, 57–61. 10.3922/j.psns.2012.1.08
- Pressler, S. J., Harrison, J. M., Titler, M., Koelling, T. M., Jung, M., Dorsey, S. G., Bakoyannis, G., Riley, P. L., Hoyland-Domenico, L., & Giordani, B. (2017). APOE  $\epsilon$ 4 and memory among patients with heart failure. *Western Journal of Nursing Research*, 39, 455–472. 10.1177/0193945916670145
- Sarica, A., Vasta, R., Novellino, F., Vaccaro, M. G., Cerasa, A., & Quattrone, A., Alzheimer's Disease Neuroimaging Initiative. (2018). MRI asymmetry index of hippocampal subfields increases through the continuum from the mild cognitive impairment to the Alzheimer's disease. *Frontiers in Neuroscience*, 12, 576. 10.3389/fnins.2018.00576
- Schmidt, M. (1996). *Rey Auditory Verbal Learning Test: RAVLT: A handbook*. Western Psychological Services.
- Sienski, G., Narayan, P., Bonner, J. M., Kory, N., Boland, S., Arczewska, A. A., Ralvenius, W. T., Akay, L., Lockshin, E., He, L., Milo, B., Graziosi, A., Baru, V., Lewis, C. A., Kellis, M., Sabatini, D. M., Tsai, L.-H., & Lindquist, S. (2021). APOE $\epsilon$ 4 disrupts intracellular lipid homeostasis in human iPSC-derived glia. *Science Translational Medicine*, 13, eaaz4564. 10.1126/scitranslmed.aaz4564
- Simonoff, J. S. (2003). *Analyzing categorical data*. Springer.
- Sullivan, K. J., Liu, A., Chang, C.-C. H., Cohen, A. D., Lopresti, B. J., Minhas, D. S., Laymon, C. M., Klunk, W. E., Aizenstein, H., Nadkarni, N. K., Loewenstein, D., Kamboh, M. I., Ganguli, M., & Snitz, B. E. (2021). Alzheimer's disease pathology in a community-based sample of older adults without dementia: The MYHAT neuroimaging study. *Brain Imaging and Behavior*, 15, 1355–1363. 10.1007/s11682-020-00334-2
- Sutphen, C. L., Jasielec, M. S., Shah, A. R., Macy, E. M., Xiong, C., Vlassenko, A. G., Benzinger, T. L. S., Stoops, E. E. J., Vanderstichele, H. M. J., Brix, B., Darby, H. D., Vandijck, M. L. J., Ladenson, J. H., Morris, J. C., Holtzman, D. M., & Fagan, A. M. (2015). Longitudinal cerebrospinal fluid biomarker changes in preclinical Alzheimer disease during middle age. *JAMA Neurology*, 72, 1029–1042. 10.1001/jamaneurol.2015.1285
- Tan, C. H., Hyman, B. T., Tan, J. J. X., Hess, C. P., Dillon, W. P., Schellenberg, G. D., Besser, L. M., Kukull, W. A., Kauppi, K., McEvoy, L. K., Andreassen, O. A., Dale, A. M., Fan, C. C., & Desikan, R. S.



- (2017). Polygenic hazard scores in preclinical Alzheimer disease. *Annals of Neurology*, 82, 484–488. 10.1002/ana.25029
- van den Berg, E., Poos, J. M., Jiskoot, L. C., Heijnen, L. M., Franzen, S., Steketee, R. M. E., Meijboom, R., de Jong, F. J., Seelaar, H., van Swieten, J. C., & Papma, J. M. (2020). Differences in discriminability and response bias on Rey Auditory Verbal Learning Test delayed recognition in behavioral variant frontotemporal dementia and Alzheimer's disease. *Journal of the International Neuropsychological Society*, 26, 918–926. 10.1017/S155617720000375
- Wang, K.-S. (2016). Linear and non-linear mixed models in longitudinal studies and complex survey data. *Journal of Biometrics and Biostatistics*, 7, 2. 10.4172/2155-6180.1000290
- Weller, J., & Budson, A. (2018). Current understanding of Alzheimer's disease diagnosis and treatment. *F1000Research*, 7. 10.12688/f1000research.14506.1
- West, B. T., Welch, K. B., & Galecki, A. T. (2014). *Linear mixed models: A practical guide using statistical software* (2nd ed.). CRC Press.

### **Call for Papers Special Issue for 2024: Addressing Health Misinformation**

We are pleased to announce plans for a special issue of Nursing Research to be published in March 2024 with earlier, online, publication-ahead-of print on innovative research designed to counteract health misinformation. Misinformation thrives in the absence of easily accessible, credible information, limited or contradictory information, and emotionally conveyed and amplified reports. Misinformation also occurs when there is societal division and in situations of distrust. Research is needed to better understand how people are exposed to and affected by misinformation, how misinformation may vary across populations, and on effective strategies to prevent and address health misinformation such as improved health communication, efficacy to make informed decisions about health and health care, and increased health literacy. Research reports can include studies that are basic or clinical, quantitative or qualitative, and descriptive or interventional. Methods papers can be briefs or full-length. Queries to the editor are welcome at [pickler.l@osu.edu](mailto:pickler.l@osu.edu). Manuscripts are due electronically by **July 15, 2023** via <http://www.editorialmanager.com/nres/mainpage.html>. The cover letter should note that the paper is being submitted in response to the Call for Methods to Address Health Misinformation. Authors should consult the Guide for Authors at <https://journals.lww.com/nursingresearchonline/Pages/informationforauthors.aspx>